Skip to content

Author

Naomi Scheinerman

We have 2 of 18 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Regulating the Revolution

The 2012 discovery of CRISPR-Cas9, a revolutionary gene editing tool, embroiled scientists, ethicists, policymakers, and patient advocates in seemingly intractable conversations regarding the moral, social, and political implications of editing DNA. Simultaneously, the regulatory and governance environment into which t...

Naomi Scheinerman · 0 citations
Review Aug 2026

AI-based augmentation of oncology clinical trials.

It is argued that achieving the potential of AI in oncology clinical trials will require rigorous prospective validation, harmonized regulatory standards, and coordination among clinicians, trialists, regulators, industry and patients.

Andrea Villa, A. Eadie, David Synnott et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.